310 related articles for article (PubMed ID: 19898288)
1. Potential application of late sodium current blockade in the treatment of heart failure and atrial fibrillation.
Doshi D; Morrow JP
Rev Cardiovasc Med; 2009; 10 Suppl 1():S46-52. PubMed ID: 19898288
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation.
Verrier RL; Kumar K; Nieminen T; Belardinelli L
Europace; 2013 Mar; 15(3):317-24. PubMed ID: 23220484
[TBL] [Abstract][Full Text] [Related]
3. Is ranolazine an antiarrhythmic drug?
Eckhardt LL; Teelin TC; January CT
Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H1989-91. PubMed ID: 18375723
[No Abstract] [Full Text] [Related]
4. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.
Sossalla S; Wagner S; Rasenack EC; Ruff H; Weber SL; Schöndube FA; Tirilomis T; Tenderich G; Hasenfuss G; Belardinelli L; Maier LS
J Mol Cell Cardiol; 2008 Jul; 45(1):32-43. PubMed ID: 18439620
[TBL] [Abstract][Full Text] [Related]
5. Enhanced late na(+) currents in atrial fibrillation new drug target or just an epiphenomenon?
Schotten U; Verheule S; Kerfant BG; Greiser M
J Am Coll Cardiol; 2010 May; 55(21):2343-5. PubMed ID: 20488305
[No Abstract] [Full Text] [Related]
6. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium.
Sossalla S; Kallmeyer B; Wagner S; Mazur M; Maurer U; Toischer K; Schmitto JD; Seipelt R; Schöndube FA; Hasenfuss G; Belardinelli L; Maier LS
J Am Coll Cardiol; 2010 May; 55(21):2330-42. PubMed ID: 20488304
[TBL] [Abstract][Full Text] [Related]
7. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.
Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC
J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Fredj S; Sampson KJ; Liu H; Kass RS
Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
[TBL] [Abstract][Full Text] [Related]
9. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes.
Song Y; Shryock JC; Belardinelli L
Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H2031-9. PubMed ID: 18310511
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine: an antianginal drug with antiarrhythmic properties.
Tamargo J; Caballero R; Delpón E
Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
[TBL] [Abstract][Full Text] [Related]
11. Too little, too late: chasing atrial fibrillation with sodium channel antagonists.
Anderson ME
J Cardiovasc Electrophysiol; 2006 Jun; 17(6):655-6. PubMed ID: 16836717
[No Abstract] [Full Text] [Related]
12. Pathophysiology and pharmacology of the cardiac "late sodium current.".
Zaza A; Belardinelli L; Shryock JC
Pharmacol Ther; 2008 Sep; 119(3):326-39. PubMed ID: 18662720
[TBL] [Abstract][Full Text] [Related]
13. Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
Makielski JC; Valdivia CR
Br J Pharmacol; 2006 May; 148(1):4-6. PubMed ID: 16520741
[TBL] [Abstract][Full Text] [Related]
14. Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.
Burashnikov A; Di Diego JM; Barajas-Martínez H; Hu D; Cordeiro JM; Moise NS; Kornreich BG; Belardinelli L; Antzelevitch C
Circ Heart Fail; 2014 Jul; 7(4):627-33. PubMed ID: 24874201
[TBL] [Abstract][Full Text] [Related]
15. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness.
Milberg P; Frommeyer G; Ghezelbash S; Rajamani S; Osada N; Razvan R; Belardinelli L; Breithardt G; Eckardt L
Europace; 2013 May; 15(5):761-9. PubMed ID: 23376977
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiologic changes in heart failure: focus on pacemaker channels.
Sartiani L; Stillitano F; Cerbai E; Mugelli A
Can J Physiol Pharmacol; 2009 Feb; 87(2):84-90. PubMed ID: 19234571
[TBL] [Abstract][Full Text] [Related]
17. Role of late sodium channel current block in the management of atrial fibrillation.
Burashnikov A; Antzelevitch C
Cardiovasc Drugs Ther; 2013 Feb; 27(1):79-89. PubMed ID: 23108433
[TBL] [Abstract][Full Text] [Related]
18. The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers.
Fedida D; Orth PM; Hesketh JC; Ezrin AM
J Cardiovasc Electrophysiol; 2006 May; 17 Suppl 1():S71-S78. PubMed ID: 16686685
[TBL] [Abstract][Full Text] [Related]
19. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current.
Undrovinas AI; Belardinelli L; Undrovinas NA; Sabbah HN
J Cardiovasc Electrophysiol; 2006 May; 17 Suppl 1(Suppl 1):S169-S177. PubMed ID: 16686675
[TBL] [Abstract][Full Text] [Related]
20. The electrophysiological properties of ranolazine: a metabolic anti-ischemic drug or an energy-efficient antiarrhythmic agent?
Cingolani E; Lepor NE; Singh BN
Rev Cardiovasc Med; 2011; 12(3):136-42. PubMed ID: 22080924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
